JP2018529656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529656A5 JP2018529656A5 JP2018509504A JP2018509504A JP2018529656A5 JP 2018529656 A5 JP2018529656 A5 JP 2018529656A5 JP 2018509504 A JP2018509504 A JP 2018509504A JP 2018509504 A JP2018509504 A JP 2018509504A JP 2018529656 A5 JP2018529656 A5 JP 2018529656A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- dll3
- cancer cells
- ihc assay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 102100036466 Delta-like protein 3 Human genes 0.000 claims 8
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 8
- 238000003556 assay Methods 0.000 claims 8
- 229940127276 delta-like ligand 3 Drugs 0.000 claims 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562207830P | 2015-08-20 | 2015-08-20 | |
| US62/207,830 | 2015-08-20 | ||
| US201662323998P | 2016-04-18 | 2016-04-18 | |
| US62/323,998 | 2016-04-18 | ||
| US201662373906P | 2016-08-11 | 2016-08-11 | |
| US62/373,906 | 2016-08-11 | ||
| PCT/US2016/047870 WO2017031458A2 (en) | 2015-08-20 | 2016-08-19 | Anti-dll3 antibody drug conjugates and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018529656A JP2018529656A (ja) | 2018-10-11 |
| JP2018529656A5 true JP2018529656A5 (Direct) | 2019-09-26 |
Family
ID=58052015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509504A Ceased JP2018529656A (ja) | 2015-08-20 | 2016-08-19 | 抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20180243435A1 (Direct) |
| EP (1) | EP3337517A4 (Direct) |
| JP (1) | JP2018529656A (Direct) |
| KR (1) | KR20180041717A (Direct) |
| CN (1) | CN108136015A (Direct) |
| AU (1) | AU2016308365A1 (Direct) |
| BR (1) | BR112018003269A2 (Direct) |
| CA (1) | CA2996165A1 (Direct) |
| CL (2) | CL2018000458A1 (Direct) |
| CO (1) | CO2018001624A2 (Direct) |
| EA (1) | EA201890530A1 (Direct) |
| HK (1) | HK1257056A1 (Direct) |
| IL (1) | IL257645A (Direct) |
| MX (1) | MX2018002166A (Direct) |
| PE (1) | PE20181292A1 (Direct) |
| PH (1) | PH12018500380A1 (Direct) |
| TW (1) | TW201718026A (Direct) |
| UY (1) | UY36862A (Direct) |
| WO (1) | WO2017031458A2 (Direct) |
| ZA (1) | ZA201801401B (Direct) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016263808B2 (en) | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| EP3525829A1 (en) * | 2016-10-11 | 2019-08-21 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CR20200196A (es) | 2017-10-13 | 2020-06-05 | Harpoon Therapeutics Inc | Proteínas trispecìficas y mètodos de uso |
| SG11202005595YA (en) * | 2018-01-15 | 2020-07-29 | Nanjing Legend Biotech Co Ltd | Antibodies and variants thereof against tigit |
| SG11202011330PA (en) | 2018-05-14 | 2020-12-30 | Harpoon Therapeutics Inc | Binding moiety for conditional activation of immunoglobulin molecules |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN113874526A (zh) * | 2019-03-08 | 2021-12-31 | 肿瘤实验室诊断有限公司 | 癌症的诊断和预后 |
| CN114245806A (zh) | 2019-05-14 | 2022-03-25 | 哈普恩治疗公司 | EpCAM结合蛋白及使用方法 |
| MX2021015095A (es) * | 2019-06-07 | 2022-03-22 | Mythic Therapeutics Inc | Construcciones de proteínas de unión a antígenos y usos de estos. |
| CN115038718B (zh) * | 2019-11-08 | 2024-07-02 | 山东先声生物制药有限公司 | 抗人程序性死亡配体-1（pd-l1）的抗体及其用途 |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| WO2021127525A1 (en) * | 2019-12-20 | 2021-06-24 | Anthos Therapeutics, Inc. | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies |
| US20230227577A1 (en) * | 2020-05-05 | 2023-07-20 | Oncorus, Inc. | Anti-dll3 antibodies and methods of use |
| US20240115720A1 (en) | 2021-01-13 | 2024-04-11 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
| EP4277665A1 (en) | 2021-01-13 | 2023-11-22 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
| US20240317856A1 (en) * | 2021-05-10 | 2024-09-26 | Amgen Inc. | Dosing regimen for combination therapy targeting dll3 and pd-1 |
| CN116271079B (zh) * | 2021-07-30 | 2025-11-14 | 上海复旦张江生物医药股份有限公司 | 一种抗dll3抗体及其制备方法、其药物偶联物和应用 |
| EP4378955A4 (en) * | 2021-07-30 | 2025-10-22 | Shanghai Fudan Zhangjiang Bio Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY AND PREPARATION METHOD THEREOF, DRUG CONJUGATE AND APPLICATION THEREOF |
| CN118159558A (zh) * | 2021-09-02 | 2024-06-07 | 纪念斯隆-凯特琳癌症中心 | 抗dll3抗体和其用途 |
| WO2023041041A1 (en) * | 2021-09-17 | 2023-03-23 | Wuxi Biologics (Shanghai) Co., Ltd. | D3-binding molecules and uses thereof |
| CN114230666B (zh) * | 2021-12-20 | 2022-09-02 | 南京诺唯赞生物科技股份有限公司 | 一种t7 rna聚合酶的单克隆抗体及其制备方法 |
| CN118176020A (zh) * | 2021-12-23 | 2024-06-11 | 江苏恒瑞医药股份有限公司 | 抗dll3抗体、其抗体-药物偶联物及其医药用途 |
| CN114369162B (zh) * | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| JP2025508786A (ja) * | 2022-02-23 | 2025-04-10 | アムジェン インコーポレイテッド | Ｄｌｌ３を標的とする癌治療 |
| CN114573698B (zh) * | 2022-03-16 | 2023-01-06 | 沈阳三生制药有限责任公司 | 一种FcRn抗原结合蛋白及其制备方法和应用 |
| TW202423979A (zh) | 2022-08-22 | 2024-06-16 | 美商雅博得樂醫療公司 | Dll3結合分子及其用途 |
| CN116253798B (zh) * | 2022-12-15 | 2023-10-27 | 华中农业大学 | 一株针对猪δ冠状病毒S1蛋白构象表位的中和性单克隆抗体 |
| CN116217715B (zh) | 2023-01-17 | 2023-08-15 | 山东农业大学 | 基于识别不同抗原决定簇的马铃薯y病毒单克隆抗体的组合及其应用 |
| CN120676969A (zh) * | 2023-02-27 | 2025-09-19 | 苏州盛迪亚生物医药有限公司 | 抗dll3抗体、其抗体-药物偶联物及其医药用途 |
| WO2025190281A1 (en) * | 2024-03-11 | 2025-09-18 | Lepu Biopharma Co., Ltd. | Anti-dll3 antibodies and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20150091A1 (es) * | 2012-02-24 | 2015-02-16 | Stem Centrx Inc | Anticuerpos anti-sez6 y metodos de empleo |
| EP3093294A1 (en) * | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Dll3 modulators and methods of use |
| EP2839860B1 (en) * | 2012-10-12 | 2019-05-01 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| SMT201900339T1 (it) * | 2013-02-22 | 2019-07-11 | Medimmune Ltd | Coniugati anticorpo anti-dll3/pbd e loro usi |
| JP2016518382A (ja) * | 2013-04-26 | 2016-06-23 | ピエール、ファーブル、メディカマン | Ａｘｌ抗体薬物複合体および癌の治療のためのその使用 |
| CN105873612A (zh) * | 2013-08-28 | 2016-08-17 | 施特姆森特克斯股份有限公司 | 改造的抗-dll3缀合物以及应用方法 |
| WO2015031698A1 (en) * | 2013-08-28 | 2015-03-05 | Stem Centrx, Inc. | Site-specific antibody conjugation methods and compositions |
| EP3054984A1 (en) * | 2013-10-11 | 2016-08-17 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US9950078B2 (en) * | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054986B1 (en) * | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054983B1 (en) * | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
-
2016
- 2016-08-19 EP EP16837930.3A patent/EP3337517A4/en not_active Withdrawn
- 2016-08-19 MX MX2018002166A patent/MX2018002166A/es unknown
- 2016-08-19 KR KR1020187007525A patent/KR20180041717A/ko not_active Withdrawn
- 2016-08-19 WO PCT/US2016/047870 patent/WO2017031458A2/en not_active Ceased
- 2016-08-19 CA CA2996165A patent/CA2996165A1/en not_active Abandoned
- 2016-08-19 AU AU2016308365A patent/AU2016308365A1/en not_active Abandoned
- 2016-08-19 TW TW105126609A patent/TW201718026A/zh unknown
- 2016-08-19 PE PE2018000271A patent/PE20181292A1/es unknown
- 2016-08-19 HK HK18116192.2A patent/HK1257056A1/zh unknown
- 2016-08-19 UY UY0001036862A patent/UY36862A/es not_active Application Discontinuation
- 2016-08-19 BR BR112018003269A patent/BR112018003269A2/pt not_active Application Discontinuation
- 2016-08-19 JP JP2018509504A patent/JP2018529656A/ja not_active Ceased
- 2016-08-19 US US15/753,509 patent/US20180243435A1/en not_active Abandoned
- 2016-08-19 CN CN201680061029.8A patent/CN108136015A/zh active Pending
- 2016-08-19 EA EA201890530A patent/EA201890530A1/ru unknown
-
2018
- 2018-02-20 PH PH12018500380A patent/PH12018500380A1/en unknown
- 2018-02-20 CL CL2018000458A patent/CL2018000458A1/es unknown
- 2018-02-20 CO CONC2018/0001624A patent/CO2018001624A2/es unknown
- 2018-02-20 IL IL257645A patent/IL257645A/en unknown
- 2018-02-28 ZA ZA2018/01401A patent/ZA201801401B/en unknown
- 2018-12-21 CL CL2018003758A patent/CL2018003758A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529656A5 (Direct) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| JP2017537066A5 (Direct) | ||
| JP2014177455A5 (Direct) | ||
| JP2013518107A5 (Direct) | ||
| JP2017509667A5 (Direct) | ||
| JP2012255026A5 (Direct) | ||
| JP2014520248A5 (Direct) | ||
| JP2014507446A5 (Direct) | ||
| MX362400B (es) | Composicion farmaceutica que comprende olmesartan medoxomilo y rosuvastatina o su sal. | |
| MX2009012598A (es) | Formas de dosis que comprenden vx-950 y su regimen de dosificacion. | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| MX2023002994A (es) | Formas de dosificacion oral y de liberacion controlada gastrorresistentes. | |
| JP2017531686A5 (Direct) | ||
| JP2015507020A5 (Direct) | ||
| JP2017516827A5 (Direct) | ||
| JP2019517507A5 (Direct) | ||
| JP2021505669A5 (Direct) | ||
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| JP2017527551A5 (Direct) | ||
| JP2019515942A5 (Direct) | ||
| JP2017517574A5 (Direct) | ||
| CN110049765A (zh) | 一种组合、其应用及治疗方法 | |
| JP2019518052A5 (Direct) | ||
| NI201400082A (es) | Composición de nitazoxanida mejorada y proceso para prepararla |